Abstract
Patients with malignant primary and metastatic brain tumors have a poor prognosis, despite developments in diagnostic and therapeutic modalities. Therefore in the past decade a search for new therapeutic possibilities has started. The inhibition of angiogenesis, the sprouting of new capillaries from preexisting vasculature, which is an absolute requirement for the growth of tumors beyond a size of a few cubic millimeters, is one of the most promising approaches with which to influence tumor growth. This review focuses on the critical role of angiogenesis in the development of normal brain and the blood-brain barrier. We discuss the importance of angiogenesis in the formation of malignant brain tumors and in blood-brain barrier function in these tumors and possible consequences of altered blood-brain barrier properties for antiangiogenic therapy. Furthermore, results of current clinical trials with antiangiogenic drugs are reviewed, and clinical perspectives of antiangiogenic therapy in malignant brain tumors are outlined.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 25 May 1999 Accepted: 7 January 2000
Rights and permissions
About this article
Cite this article
Reijneveld, J., Voest, E. & Taphoorn, M. Angiogenesis in malignant primary and metastatic brain tumors. J Neurol 247, 597–608 (2000). https://doi.org/10.1007/s004150070128
Issue Date:
DOI: https://doi.org/10.1007/s004150070128